EG 427 raised €27 million in a Series B funding round led by Andera Partners and Bpifrance to enhance its clinical study of EG110A and support its proprietary vector technology platform in neuro-urology.

Information on the Target

EG 427 is a leading biotechnology company focused on the development of precision genomic medicine targeted at prevalent chronic neurological diseases. Recently, the company successfully closed a €27 million Series B funding round, which was jointly led by Andera Partners and Bpifrance. This funding will be instrumental in financing their ongoing Phase 1b/2a clinical study of EG110A, which evaluates the therapy's safety profile and initial efficacy results.

The ongoing study paves the way for further clinical development in various indications with significant unmet medical needs in neuro-urology. The funds raised will also support the preclinical pipeline of EG 427, which leverages its proprietary vector technology platform known as HERMES.

Industry Overview in France

France's biotechnology sector has seen considerable growth, particularly in the fields of genomics and neurological research. With a strong emphasis on innovation, the French government, along with private inves